What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.6% in the afternoon session after the major indices ...

23 analysts are following Illumina and have set target prices ranging from $70.0 to $185.0 per share. On average, they have given the company a rating of buy. At today's prices, ILMN is trading -7.75% ...

Explore the future of proteomics where new biomarkers are redefining disease, possibly outpacing genomics. With venture capital backing and double-digit growth, the market forecasts suggest ...

In a report released today, Eve Burstein from Bernstein maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $90.00. The company’s shares clos ...

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the companys multiomics strategy ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Illumina (ILMN – Research Report) and Alpha Te ...

Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), ...

Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in multiomics.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The ...

BSE share price in focus today: Shares of BSE Ltd, one of Asia's oldest stock exchanges, plunged 5% in intraday trade on Wednesday, June 11, hitting a low of ₹ 2,855 after being placed under the ...

Here’s an interesting stock idea: The stock idea that we have for you today is Jammu & Kashmir Bank. The rise on Tuesday has taken the share price well above a key resistance. That strengthens ...